FDA Approves Ozempic for Reducing Kidney Disease Risks in Adults with Type 2 Diabetes and Chronic Kidney Disease

Ozempic, FDA Approval, Type 2 Diabetes, Chronic Kidney Disease (CKD), Kidney Disease Risks, Cardiovascular Disease Risks, Semaglutide, GLP-1 Receptor Agonist